Mounjaro®
Starting from £179.99/mo
Start journey Learn moreThe Wegovy pre-filled pen is designed for self-injection into the abdomen, thigh, or upper arm once a week. Injecting into the stomach — specifically the fatty tissue at least 5 cm from the navel — is the route most patients choose and the one Novo Nordisk's patient information, along with NHS guidance on semaglutide, confirms as suitable. If you're holding a new pen and feeling uncertain about the first injection, that is entirely normal; most patients find the process straightforward after the first or second dose, partly because the auto-injection mechanism removes the need to push a needle manually. These are prescription-only medicines, and your prescriber will confirm the injection technique that suits your situation alongside clinical assessment of your treatment.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Novo Nordisk's published Patient Information Leaflet, cross-referenced with the NHS medicines page for semaglutide, confirms the abdomen as a primary site. The injection goes into subcutaneous fat (the softer tissue just beneath the skin) rather than into muscle. For the stomach specifically, aim for the area roughly 5 cm clear of the navel in any direction, avoiding the band of skin around the waistband where tissue is sometimes thinner. Do not inject into skin that is bruised, red, broken, or recently used; rotating sites within the abdomen (upper left, lower left, upper right, lower right in a loose rotation) reduces the risk of lipohypertrophy, a localised thickening that can affect absorption over time.
The Wegovy pen does not require you to dial a dose or push a plunger. Once the pen is pressed firmly against the skin, a single button press triggers the full injection automatically. A yellow indicator confirms the dose has been delivered; keep the pen pressed for ten seconds before removing it to ensure the full volume is absorbed. This mechanism means needle anxiety is less of a barrier than many patients expect. Our detailed guide to injecting Wegovy in the stomach goes further on site selection within the abdomen.
Preparation takes under two minutes and makes a measurable difference to comfort. Wash hands thoroughly with soap and water. Remove the pen from the refrigerator around thirty minutes before injecting, cold medicine drawn from the fridge tends to sting more. Clean the skin at the chosen site with an alcohol swab and allow it to dry fully before injecting; injecting through damp skin slightly increases stinging. Remove the pen cap just before use. Alcohol swabs compatible with the pen technique are available if you need to restock.
Place the pen flat against the skin (at a right angle, not angled) and hold it steady. Press and hold the injection button until you hear or feel a click, then count ten seconds. You may see a small window indicator turn yellow or feel a second click depending on the pen version; either confirms delivery. Lift the pen straight away from the skin. A little redness at the site for a few minutes is normal. For a visual reference of the technique, our video guide to the Wegovy pen walks through each step in real time, which many patients find more reassuring than written instructions alone.
Used pens must go straight into a sharps container. A 1-litre sharps bin is the standard household size for weekly injections; your local pharmacy or council site can advise on collection.
Injection-site reactions) mild redness, a small bruise, or temporary tenderness, are the most common local side effects and usually resolve within a day or two. They are more likely if the same spot is used repeatedly, which is why rotation matters. Systemically, the side effects most associated with semaglutide treatment are gastrointestinal: nausea, constipation, loose stools, and reflux appear most often after starting or after a dose increase, typically settling within one to two weeks as the body adjusts. The STEP 1 trial, published in the New England Journal of Medicine, reported this GI pattern in the majority of participants, with most describing it as mild to moderate.
There are symptoms that need prompt medical attention rather than watchful waiting: severe stomach pain that radiates to the back (possible pancreatitis) warrants urgent assessment. Persistent vomiting leading to inability to keep fluids down, signs of a serious allergic reaction (swelling of the face or throat, difficulty breathing), or significant mood changes should all prompt contact with a GP or 111. For context on this specific safety signal, the MHRA's Yellow Card scheme allows patients to report suspected side effects directly, which contributes to ongoing safety monitoring of semaglutide. You can also report a suspected counterfeit or unlicensed pen via the same route.
If you have questions about your injection technique mid-treatment, the aftercare team at nume is available seven days a week. Detailed technique questions are best directed to your prescriber, who can review your notes and give specific advice rather than general guidance. For a broader look at how Wegovy works and what clinical review involves, our Wegovy treatment page covers the full picture.
The evidence base for subcutaneous self-injection with GLP-1 pens in clinical trials is large; patients across the STEP programme administered their own injections successfully with standard written instruction and one brief training session. That said, the first time is the first time. A question our prescribers hear regularly is whether it is possible to do something wrong and harm yourself, the honest answer is that the auto-injection design and the pen's safety lock make serious technique errors very unlikely, and the most common mistake (not keeping the pen pressed for the full ten seconds) simply means a partial dose rather than any injury.
A few practical points worth knowing before you start: the injection day can shift by up to two days either side of schedule without clinical concern, provided the minimum four-day gap between doses is maintained. If you miss a dose entirely, refer to the Patient Information Leaflet or contact your prescriber; the answer depends on how close you are to the next scheduled dose. Storage matters too, Wegovy must be kept refrigerated until use; once a pen has been used, replace the cap and store it as directed in the leaflet until it is empty and ready for the sharps bin.
For people earlier in the decision process, our weight-loss treatment overview explains how Wegovy compares with other licensed options, and if you want to understand exactly where on the stomach to inject Wegovy, including how to identify the right zones and avoid common placement mistakes, that guide covers it in full. If you want a step-by-step walkthrough of how to give a semaglutide injection in the stomach, including posture, pen angle, and what to expect as you press the button, that guide takes you through the whole process. If you are ready to explore whether Wegovy is right for you clinically, a free consultation with our prescribers is the place to start, and our guide on injecting Wegovy in the stomach, covering everything from choosing your spot to completing the injection confidently, is a useful read before your first dose.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.